17
2020-09
Acne Drug KX-826 Gel Approved for Clinical Trials in China
On 17 September 2020, 真人直营投注网站 is pleased to announce that it has received clinical trial approval from the National Medical Products Administration for the gel dosage form of KX-826 for the treatment of acne and androgenetic alopecia.
11
2020-09
Among them, 真人直营投注网站 was listed on the TOP100 Chemical Drug Research and Development Strength Rankings in China for 2020, and was also selected to enter the most important sub-list "TOP100 Chemical Pharmaceutical Research and Development Strength Rankings in China for 2020".
01
2020-09
Kintor Pharmaceutical Enters Loncar China BioPharma Index after 100 Days of Listing in HK
In August 2020, the Loncar China BioPharma Index underwent its six-monthly adjustments and restructuring, adding 14 biopharmaceutical companies, including 真人直营投注网站 (stock code: 9939.HK).
01
2020-09
Three Parties Jointly Build A Precise Cancer Treatment Platform
(September 1, 2020, Hong Kong) 真人直营投注网站 (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) signed a strategic cooperation framework agreement with Suzhou GloriousMed Biomedical Group Co., Ltd. (hereinafter referred to as “GloriousMed”) and HM Shuke (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as “HM Healthcare”), under which the three parties will create a patient-centered, integrated precise cancer treatment platform.
01
2020-09
New Start For New Journey! Kintor Relocated To Suzhou R&D Center And Industrialization Base
On 28 August 2020, 真人直营投注网站 (Stock Code: 9939.HK, hereinafter referred to as the “Kintor Pharmaceutical”), officially moved to Suzhou self-established R&D center and industrialization base, symbolising a new development chapter for Kintor Pharmaceutical.
24
2020-08
First Patient Enrolment for the COVID-19 Clinical Trial of Proxalutamide Completed
(August 24, 2020, Hong Kong) 真人直营投注网站 (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) , declared that the Clinical Trial (identifier: NCT04446429) to conduct research for Proxalutamide (GT0918) as a treatment for the coronavirus disease (“COVID-19”)has recorded the first patient enrolment in Brazil. The Company plans to enrol a total of 381 subjects and it’s expected that the enrolment will be completed in 2 months.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn